Subscribe to RSS
DOI: 10.1055/s-0040-1715137
SARS-CoV-2 and Pregnancy: A Review of the Facts
SARS-CoV-2 e gestação: uma revisão dos fatos
Abstract
Objective The present comprehensive review aims to show the full extent of what is known to date and provide a more thorough view on the effects of SARS-CoV2 in pregnancy.
Methods Between March 29 and May, 2020, the words COVID-19, SARS-CoV2, COVID-19 and pregnancy, SARS-CoV2 and pregnancy, and SARS and pregnancy were searched in the PubMed and Google Scholar databases; the guidelines from well-known societies and institutions (Royal College of Obstetricians and Gynaecologists [RCOG], American College of Obstetricians and Gynecologists [ACOG], International Society of Ultrasound in Obstetrics & Gynecology [ISUOG], Centers for Disease Control and Prevention [CDC], International Federation of Gynecology and Obstetrics [FIGO]) were also included.
Conclusion The COVID-19 outbreak resulted in a pandemic with > 3.3 million cases and 230 thousand deaths until May 2nd. It is caused by the SARS-CoV2 virus and may lead to severe pulmonary infection and multi-organ failure. Past experiences show that unique characteristics in pregnancy make pregnant women more susceptible to complications from viral infections. Yet, this has not been reported with this new virus. There are risk factors that seem to increase morbidity in pregnancy, such as obesity (body mass index [BMI] > 35), asthma and cardiovascular disease. Current reports describe an increased rate of preterm birth and C-section. Vertical transmission is still a possibility, due to a few reported cases of neonatal positive real-time polymerase chain reaction (RT-PCR) in nasal swab, amniotic fluid, and positive immunoglobulin M (IgM) in neonatal blood. Treatments must be weighed in with caution due to the lack of quality trials that prove their effectiveness and safety during pregnancy. Medical staff must use personal protective equipment in handling SARS-CoV2 suspected or positive patients and be alert for respiratory decompensations.
Resumo
Objetivo A presente revisão detalhada busca fornecer dados objetivos para avaliar o que se sabe até o momento e possibilitar uma visão mais ampla dos efeitos do SARS-CoV2 na gravidez.
Métodos Entre 29 de março e 2 de maio de 2020, foi realizada uma busca nos bancos de dados PubMed e Google Scholar com as palavras COVID-19, SARS-CoV2, COVID-19 e gravidez, SARS-CoV2 e gravidez, e SARS e gravidez. As recomendações dos principais órgãos sobre o tema também foram acessadas.
Conclusão O surto de COVID-19 resultou em uma pandemia com > 3.3 milhões de casos e 230 mil mortes até 2 de maio. É uma condição causada pelo vírus SARS-CoV2 e pode levar ao acometimento pulmonar difuso e à falência de múltiplos órgãos. Características únicas da gestante tornam essa população mais propensas a complicações de infecções virais. Até o momento, essa tendência não foi observada para esse novo vírus. Os fatores que parecem estar associados à maior morbidade materno-fetal são obesidade (índice de massa corporal [IMC] > 35), asma e doença cardiovascular. Há descrição de aumento de parto prematuro e parto cesáreo. Não se pode descartar a possibilidade de transmissão vertical da doença, devido a relatos de positividade de reação em cadeia de polimerase (RT-PCR) de swab nasal, RT-PCR de líquido amniótico e imunoglobulina M (IgM) de recém-nascidos. Tratamentos devem ser analisados caso a caso, dada a falta de qualidade de estudos que comprovem a sua eficácia e segurança na gravidez. O corpo clínico deve utilizar equipamentos de proteção individual (EPI) ao manusear pacientes suspeitos ou confirmados e ficar atento aos sinais de descompensação respiratória.
Publication History
Received: 05 May 2020
Accepted: 15 June 2020
Article published online:
29 September 2020
© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).
Thieme Revinter Publicações Ltda
Rio de Janeiro, Brazil
-
References
- 1 He J, Tao H, Yan Y, Huang SY, Xiao Y. Molecular mechanism of evolution and human infection with SARS-CoV-2. Viruses 2020; 12 (04) 428 . Doi: 10.3390/v12040428
- 2 Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y. , et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus–infected pneumonia. N Engl J Med 2020; 382 (13) 1199-1207 . Doi: 10.1056/NEJMoa2001316
- 3 World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 [Internet]. 2020 [cited 2020 Apr 10]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020
- 4 Johns Hopkins University & Medicine. Coronavirus resource center [Internet]. 2020 [cited 2020 May 4]. Available from: https://coronavirus.jhu.edu/
- 5 Liu H, Wang LL, Zhao SJ, Kwak-Kim J, Mor G, Liao AH. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. J Reprod Immunol 2020; 139: 103122 . Doi: 10.1016/j.jri.2020.103122
- 6 Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H. , et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020; 581 (7807): 221-224 DOI: 10.1038/s41586-020-2179-y.
- 7 Tang X, Wu C, Li X, Song Y, Yao X. Wu Xinkai, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev 2020; 36
- 8 Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020; 10 (02) 102-108 DOI: 10.1016/j.jpha.2020.03.001.
- 9 Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res 2011; 81: 85-164 DOI: 10.1016/B978-0-12-385885-6.00009-2.
- 10 Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M. , et al. Outcome of Coronavirus spectrum infections (SARS, MERS, COVID 1 -19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020; 2 (02) 100107 DOI: 10.1016/j.ajogmf.2020.100107.
- 11 Della Gatta AN, Rizzo R, Pilu G, Simonazzi G. Coronavirus disease 2019 during pregnancy: a systematic review of reported cases. Am J Obstet Gynecol 2020
- 12 Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis 2020; 94: 44-48 DOI: 10.1016/j.ijid.2020.03.004.
- 13 Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope 2020; 130 (07) 1787 DOI: 10.1002/lary.28692 [ahead of print].
- 14 Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies. Acta Obstet Gynecol Scand 2020; 99 (07) 823-829 DOI: 10.1111/aogs.13867.
- 15 Kokkinakis I, Selby K, Favrat B, Genton B, Cornuz J. [Covid-19 diagnosis : clinical recommendations and performance of nasopharyngeal swab-PCR]. Rev Med Suisse 2020; 16 (689) 699-701
- 16 Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R. , et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (15) 458-464 DOI: 10.15585/mmwr.mm6915e3.
- 17 Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol 2017; 17 (08) 469-482 DOI: 10.1038/nri.2017.64.
- 18 O'Day MP. Cardio-respiratory physiological adaptation of pregnancy. Semin Perinatol 1997; 21 (04) 268-275 DOI: 10.1016/s0146-0005(97)80069-9.
- 19 Bobrowski RA. Pulmonary physiology in pregnancy. Clin Obstet Gynecol 2010; 53 (02) 285-300 DOI: 10.1097/GRF.0b013e3181e04776.
- 20 Meijer WJ, van Noortwijk AGA, Bruinse HW, Wensing AMJ. Influenza virus infection in pregnancy: a review. Acta Obstet Gynecol Scand 2015; 94 (08) 797-819 DOI: 10.1111/aogs.12680.
- 21 Raichel L, Romanyuk V, Sergienko R, Wiznitzer A, Sheiner E. 547: Pneumonia during pregnancy: radiological characteristics, predisposing factors, and pregnancy outcomes. Am J Obstet Gynecol 2009; 201 (6, Suppl) S203-S204 DOI: 10.1016/j.ajog.2009.10.412.
- 22 World Health Organization. Regional Office for the Eastern Mediterranean. MERS Situation Update [Internet]. 2019 [cited 2020 Apr 10]. Available from: https://applications.emro.who.int/docs/EMRPUB-CSR-241-2019-EN.pdf?ua=1&ua=1&ua=1&ua=1&ua=1&ua=1
- 23 Ahmed AE. The predictors of 3- and 30-day mortality in 660 MERS-CoV patients. BMC Infect Dis 2017; 17 (01) 615 DOI: 10.1186/s12879-017-2712-2.
- 24 Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection during pregnancy: Report of two cases & review of the literature. J Microbiol Immunol Infect 2019; 52 (03) 501-503 DOI: 10.1016/j.jmii.2018.04.005.
- 25 World Health Organization. Summary table of SARS cases by country, November 1, 2002- August 7, 2003 [Internet]. 2020 [cited 2020 Apr 10]. Available from: https://www.who.int/csr/sars/country/2003_08_15/en/
- 26 Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) Coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human Coronavirus infections. Viruses 2020; 12 (02) 194 DOI: 10.3390/v12020194.
- 27 Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC. , et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 2004; 191 (01) 292-297 DOI: 10.1016/j.ajog.2003.11.019.
- 28 Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W. , et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020; 395 (10226): 809-815 DOI: 10.1016/S0140-6736(20)30360-3.
- 29 Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein K. , et al. COVID-19 infection among asymptomatic and symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM 2020; 2 (02) 100118 DOI: 10.1016/j.ajogmf.2020.100118.
- 30 Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020; 323 (13) 1239-1242 DOI: 10.1001/jama.2020.2648.
- 31 Kimberlin DW, Stagno S. Can SARS-CoV-2 infection be acquired in utero?: More definitive evidence is needed. JAMA 2020; 323 (18) 1788-1789 DOI: 10.1001/jama.2020.4868.
- 32 Baud D, Greub G, Favre G, Gengler C, Jaton K, Dubruc E, Pomar L. , et al. Second-trimester miscarriage in a pregnant woman with SARS-CoV-2 infection. JAMA 2020; 323 (21) 2198-2200 DOI: 10.1001/jama.2020.7233.
- 33 Elshafeey F, Magdi R, Hindi N, Elshebiny M, Farrag N, Mahdy S. , et al. A systematic scoping review of COVID-19 during pregnancy and childbirth. Int J Gynaecol Obstet 2020; 150 (01) 47-52 DOI: 10.1002/ijgo.13182.
- 34 Purisch SE, Gyamfi-Bannerman C. Epidemiology of preterm birth. Semin Perinatol 2017; 41 (07) 387-391 DOI: 10.1053/j.semperi.2017.07.009.
- 35 Zamaniyan M, Ebadi A, Aghajanpoor Mir S, Rahmani Z, Haghshenas M, Azizi S. Preterm delivery in pregnant woman with critical COVID-19 pneumonia and vertical transmission. Prenat Diagn 2020; DOI: 10.1002/pd.5713.
- 36 Gidlöf S, Savchenko J, Brune T, Josefsson H. COVID-19 in pregnancy with comorbidities: More liberal testing strategy is needed. Acta Obstet Gynecol Scand 2020; 99 (07) 948-949 DOI: 10.1111/aogs.13862.
- 37 Koumoutsea EV, Vivanti AJ, Shehata N, Benachi A, Le Gouez A, Desconclois C. , et al. COVID-19 and acute coagulopathy in pregnancy. J Thromb Haemost 2020; ••• DOI: 10.1111/jth.14856.
- 38 Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection in pregnancy: information for healthcare professionals: Version 8. London: RCOG; 2020
- 39 American College of Obstetricians and Gynecologists. Novel Coronavirus 2019 (COVID-19): practice advisory [Internet]. 2020 [cited 2020 Apr 24]. Available from: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/03/novel-coronavirus-2019
- 40 Poon LC, Yang H, Kapur A, Melamed N, Dao B, Divakar H. , et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. Int J Gynaecol Obstet 2020; 149 (03) 273-286 DOI: 10.1002/ijgo.13156.
- 41 Poon LC, Yang H, Lee JCS, Copel JA, Leung TY, Zhang Y. , et al. ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals. Ultrasound Obstet Gynecol 2020; 55 (05) 700-708 DOI: 10.1002/uog.22013.
- 42 Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) - Caring for pregnant women [Internet]. 2020 [cited 2020 Apr 25]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/inpatient-obstetric-healthcare-guidance.html
- 43 LaCourse SM, John-Stewart G, Adams Waldorf KM. Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials. Clin Infect Dis 2020; 444
- 44 Little BB. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet Gynecol 1999; 93 (5 Pt 2): 858-868 DOI: 10.1016/s0029-7844(98)00444-x.
- 45 Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020; 177: 104762 DOI: 10.1016/j.antiviral.2020.104762.
- 46 Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M. , et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30 (03) 269-271 DOI: 10.1038/s41422-020-0282-0.
- 47 Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M. , et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 105949: 105949 DOI: 10.1016/j.ijantimicag.2020.105949.
- 48 Law I, Ilett KF, Hackett LP, Page-Sharp M, Baiwog F, Gomorrai S. , et al. Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers. Br J Clin Pharmacol 2008; 65 (05) 674-679 DOI: 10.1111/j.1365-2125.2008.03111.x.
- 49 Mace KE, Arguin PM, Lucchi NW, Tan KR. Malaria Surveillance - United States, 2016. MMWR Surveill Summ 2019; 68 (05) 1-35 DOI: 10.15585/mmwr.ss6805a1.
- 50 Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A. , et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382 (24) 2327-2336
- 51 Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y. , et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395 (10236): 1569-1578 DOI: 10.1016/S0140-6736(20)31022-9.
- 52 Mulangu S, Dodd LE, Davey Jr RT, Mbaya OT, Proschan M, Mukadi D. et al; PALM Writing Group; PALM Consortium Study Team. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381 (24) 2293-2303 DOI: 10.1056/NEJMoa1910993.
- 53 Xu X, Han M, Li T, Sun W, Wang D, Fu B. , et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020; 117 (20) 10970-10975 DOI: 10.1073/pnas.2005615117.
- 54 Hoeltzenbein M, Beck E, Rajwanshi R, Skorpen CG, Berber E, Schaefer C, Østensen M. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum 2016; 46 (02) 238-245 DOI: 10.1016/j.semarthrit.2016.05.004.
- 55 Saito J, Yakuwa N, Kaneko K, Takai C, Goto M, Nakajima K. , et al. Tocilizumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk and infant serum. Rheumatology (Oxford) 2019; 58 (08) 1505-1507 DOI: 10.1093/rheumatology/kez100.
- 56 Rajkumar RP. COVID-19 and mental health: A review of the existing literature. Asian J Psychiatr 2020; 52: 102066 DOI: 10.1016/j.ajp.2020.102066.
- 57 Corbett GA, Milne SJ, Hehir MP, Lindow SW, O'connell MP. Health anxiety and behavioural changes of pregnant women during the COVID-19 pandemic. Eur J Obstet Gynecol Reprod Biol 2020; 249: 96-97 DOI: 10.1016/j.ejogrb.2020.04.022.